---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-044318"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T07:59:05.053583+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Corcept Q3 revenue $182.5M (+48% YoY); guides FY2024 to $675-700M; positive GRADIENT results

## Summary
- Q3 revenue $182.5M (+48% YoY); diluted EPS $0.41 vs $0.28; net income $47.2M.
- FY2024 revenue guidance raised to $675-700M from $640-670M; strong Korlym prescriber and patient growth.
- Cash and investments $547.6M; repurchased 870K shares for $23.4M in Q3.
- Phase 3 GRADIENT in Cushing's syndrome: significant improvements in BP, glucose, weight vs placebo; no hypokalemia or endometrial hypertrophy.
- NDA for relacorilant in Cushing's to be submitted this quarter; ROSELLA (ovarian cancer) and DAZALS (ALS) data expected by year-end.

## SEC filing metadata
- accession: 0001628280-24-044318
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828024044318/0001628280-24-044318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828024044318/cort-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-044318
- JSON: https://secwatch.observer/filing/0001628280-24-044318.json
- Plain text: https://secwatch.observer/filing/0001628280-24-044318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.